PMID- 33705643
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20211231
IS  - 1303-6165 (Electronic)
IS  - 1300-0144 (Print)
IS  - 1300-0144 (Linking)
VI  - 51
IP  - 4
DP  - 2021 Aug 30
TI  - Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem 
      against Staphylococcus aureus with reduced susceptibility to vancomycin.
PG  - 2150-2158
LID - 10.3906/sag-1910-166 [doi]
AB  - BACKGROUND/AIM: We investigated the synergistic effect between vancomycin and 
      beta-lactams against vancomycin-susceptible (VSSA) and nonsusceptible MRSA isolates 
      [heterogeneous vancomycin-intermediate S. aureus (hVISA) and VISA]. MATERIALS AND 
      METHODS: A total of 29 MRSA, including 6 VISA, 14 hVISA, and 9 VSSA isolates, 
      were subjected to a microbroth dilu- tion-minimum inhibitory concentration (MIC) 
      checkerboard using vancomycin combined with cefotaxime, imipenem, or meropenem. 
      To confirm synergistic activity, the representative strains of VISA, hVISA, and 
      VSSA were then selected for the time-kill curve method. RESULTS: The combination 
      of vancomycin with imipenem, meropenem, or cefotaxime exhibited synergistic 
      effects against 17 (2 VISA, 9 hVISA, and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 
      VSSA), and 5 (3 VISA and 2 hVISA) isolates, respectively. Additive and 
      indifferent effects were found in the remaining isolates, but no antagonistic 
      effect was observed. Using time-kill assay, the vancomycin combined with either 
      imipenem or cefotaxime demonstrated synergism against both VISA and hVISA 
      isolates, while the synergistic effect with meropenem was obtained only in the 
      VISA isolates. CONCLUSION: This study demonstrated in vitro enhanced 
      antibacterial activity of vancomycin plus beta-lactams against clinical hVISA or 
      VISA isolates. These combinations may be an alternative treatment for MRSA 
      infections in clinical practice.
CI  - This work is licensed under a Creative Commons Attribution 4.0 International 
      License.
FAU - Srisrattakarn, Arpasiri
AU  - Srisrattakarn A
AUID- ORCID: 0000-0003-2103-9716
AD  - Centre for Research and Development of Medical Diagnostic Laboratories, Faculty 
      of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
FAU - Chaiyapoke, Chonthicha
AU  - Chaiyapoke C
AUID- ORCID: 0000-0002-1430-8570
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
FAU - Booncharoen, Sirikarn
AU  - Booncharoen S
AUID- ORCID: 0000-0001-5644-8566
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
FAU - Wongthong, Sujintana
AU  - Wongthong S
AUID- ORCID: 0000-0002-6580-6975
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
AD  - Faculty of Medical Technology, Nakhon Ratchasima College, Nakhon Ratchasima, 
      Thailand
FAU - Chanawong, Aroonwadee
AU  - Chanawong A
AUID- ORCID: 0000-0002-6849-3820
AD  - Centre for Research and Development of Medical Diagnostic Laboratories, Faculty 
      of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
FAU - Tippayawat, Patcharaporn
AU  - Tippayawat P
AUID- ORCID: 0000-0002-4452-1284
AD  - Centre for Research and Development of Medical Diagnostic Laboratories, Faculty 
      of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
FAU - Tavichakorntrakool, Ratree
AU  - Tavichakorntrakool R
AUID- ORCID: 0000-0002-8159-0764
AD  - Centre for Research and Development of Medical Diagnostic Laboratories, Faculty 
      of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
FAU - Lulitanond, Aroonlug
AU  - Lulitanond A
AUID- ORCID: 0000-0002-4735-5074
AD  - Centre for Research and Development of Medical Diagnostic Laboratories, Faculty 
      of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
AD  - Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon 
      Kaen University, Khon Kaen, Thailand
LA  - eng
PT  - Journal Article
DEP - 20210830
PL  - Turkey
TA  - Turk J Med Sci
JT  - Turkish journal of medical sciences
JID - 9441758
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (beta-Lactams)
RN  - 6Q205EH1VU (Vancomycin)
RN  - 71OTZ9ZE0A (Imipenem)
RN  - FV9J3JU8B1 (Meropenem)
RN  - N2GI8B1GK7 (Cefotaxime)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology/therapeutic use
MH  - Cefotaxime/*pharmacology
MH  - Drug Synergism
MH  - Humans
MH  - Imipenem/*pharmacology
MH  - Meropenem/*pharmacology
MH  - Microbial Sensitivity Tests
MH  - Staphylococcal Infections/*drug therapy
MH  - Staphylococcus aureus/*drug effects
MH  - Vancomycin/*pharmacology
MH  - Vancomycin Resistance/drug effects
MH  - beta-Lactams/*pharmacology
PMC - PMC8569772
OTO - NOTNLM
OT  - methicillin-resistant Staphylococcus aureus
OT  - synergy
OT  - vancomycin
OT  - vancomycin resistance
OT  - beta-Lactams
COIS- CONFLICT OF INTEREST: The authors declare that they have no conflicts of 
      interest.
EDAT- 2021/03/12 06:00
MHDA- 2022/01/01 06:00
PMCR- 2021/08/30
CRDT- 2021/03/11 19:11
PHST- 2019/10/22 00:00 [received]
PHST- 2021/03/11 00:00 [accepted]
PHST- 2021/03/11 19:11 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
PHST- 2021/08/30 00:00 [pmc-release]
AID - 10.3906/sag-1910-166 [doi]
PST - epublish
SO  - Turk J Med Sci. 2021 Aug 30;51(4):2150-2158. doi: 10.3906/sag-1910-166.